Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2011

View Archived Issues

Interim phase I data on E-7080 in hepatocellular carcinoma disclosed at ILCA meeting

FDA advisory committee to review rivaroxaban NDA following ROCKET AF study

Bayer discloses preclinical data on dual vasopressin V1A/V2 receptor antagonist

Long-term therapy with cysteamine eye drops assessed in subjects with cystinosis

Aeterna Zentaris selective ERK-1/ERK-2 inhibitor shows anticancer activity in vivo

Novel biocrea phosphodiesterase 2 inhibitor has procognitive effects

High Point Pharmaceuticals claims new heme oxygenase 1 production inducers and/or activity enhancers

Transgene Biotek develops new recombinant therapeutic for liver cancer

GSK receives BARDA contract to develop boron-based antibiotic

New microRNA-based therapies disclosed by University of Miami

Novel SsIR-based vaccines created against nematode infection

Okayama University claims new iodobenzyl-bleomycin analogues

TWi Biotechnology completes enrollment in phase IIb AC-201 trial

Phase II MG-01CI trial meets primary endpoints

BHR Pharma advances phase III SyNAPSe trial

Topline phase IIIb data on Xiaflex in Dupuytren's contracture with multiple palpable cords

ImmunoCellular Therapeutics updates on phase II ICT-107 trial

FDA clears Fujirebio immunoassay for use in ROMA algorithm to determine ovarian cancer risk

Zytiga approved in Europe

Debiopharm and Ascenta Therapeutics announce exclusive license agreement for AT-406

Prespecified number of events reached for unblinding of Exelixis' EXAM trial

Verona Pharma's VRP-700 significantly reduces coughing in Italian study

Novartis gains E.U. approval for Votubia

Takeda advances DPP IV inhibitor into Japanese phase III trials in type 2 diabetes

FDA updates boxed warning for all TNF-alpha inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...